Phase II Study of Lenalidomide and Darbepoetin Alfa in Myelodysplastic Syndrome (Low to Intermediate-1 Risk Category Excluding 5q Deletion).
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2015
At a glance
- Drugs Darbepoetin alfa (Primary) ; Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 26 Jan 2011 Planned end date changed from 1 Jan 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.
- 21 Oct 2010 New trial record